https://www.pharmacytimes.com/view/study-rucaparib-may-improve-progression-free-survival-in-patients-with-later-line-ovarian-cancer-with-a-brca-mutation
Rucaparib is an oral, small molecule inhibitor being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers.
progression free survivalstudyrucaparibmayimprove